Being Alive 1994 Feb 5: 2
Bristol-Myers-Squibb, the manufacturers of D4T, is reported to be
applying for the drug's licensing. Some predict that the FDA will
approve D4T sometime within the first half of this year.
Although full study data on D4T has not yet been released, we do hear
that early results show that D4T brings about a higher and more
sustained rise in T-cells than is found with current antivirals. The
anecdotal evidence says that people on D4T seem to do well.
And we should point out that the people taking D4T are those who are
intolerant of or get no efficacy from AZT/ddI/ddC. This group tends to
have T-cell counts at the lower end of the spectrum. Will D4T be even
more efficacious for those at higher T-cell levels? Will it become a
first-line drug, as AZT is today? We need more studies to answer these
Studies of 3TC are underway and no data are yet available. Glaxo, the
manufacturer of 3TC, has set up a compassionate use program for those
who are unable to use the other four available antivirals (AZT, ddI,
ddC and D4T). For information on this program, call 1.800.248.9757.